| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Sarah J Nelson | |
| P2860 | cites work | Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis | Q24608039 |
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR | Q24683340 | ||
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Mapping complex tissue architecture with diffusion spectrum magnetic resonance imaging | Q28278902 | ||
| Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI | Q28281455 | ||
| Targeting the phosphoinositide 3-kinase pathway in cancer | Q29615809 | ||
| Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas | Q30419061 | ||
| AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. | Q30490422 | ||
| Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI. | Q30579563 | ||
| Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors | Q30620964 | ||
| An automated technique for the quantitative assessment of 3D-MRSI data from patients with glioma | Q30627262 | ||
| Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging | Q30655321 | ||
| Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging | Q30777038 | ||
| The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial | Q30886853 | ||
| Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions | Q30949492 | ||
| Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression | Q30951772 | ||
| Glucocorticoid treatment of brain tumor patients: changes of apparent diffusion coefficient values measured by MR diffusion imaging | Q30966007 | ||
| Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response | Q30986317 | ||
| Diffusion tensor imaging for preoperative evaluation of tumor grade in gliomas | Q30986947 | ||
| Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. | Q48586351 | ||
| Prognostic factors for survival in adult patients with cerebral low-grade glioma. | Q48629888 | ||
| Diffusion MR imaging in glioma: does it have any role in the pre-operation determination of grading of glioma? | Q48631632 | ||
| Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria. | Q48654914 | ||
| Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. | Q48661262 | ||
| Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. | Q48797418 | ||
| Metabolic imaging of patients with intracranial tumors: H-1 MR spectroscopic imaging and PET. | Q48901413 | ||
| Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. | Q49104638 | ||
| Treatment outcomes and prognostic factors in patients with supratentorial low-grade gliomas. | Q55471524 | ||
| Comparative study of methods for determining vascular permeability and blood volume in human gliomas. | Q55471802 | ||
| Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas | Q55484160 | ||
| Localized 1H NMR spectroscopy in fifty cases of newly diagnosed intracranial tumors. | Q55484265 | ||
| Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. | Q55485347 | ||
| Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion | Q71694555 | ||
| Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis | Q79362737 | ||
| In vivo 13 carbon metabolic imaging at 3T with hyperpolarized 13C-1-pyruvate | Q80691642 | ||
| Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced pe | Q82839825 | ||
| MR-spectroscopy guided target delineation for high-grade gliomas | Q43655485 | ||
| Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy | Q43870174 | ||
| Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis | Q44137912 | ||
| Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities | Q44276666 | ||
| Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging | Q44418561 | ||
| Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging | Q44660901 | ||
| Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas | Q44663935 | ||
| Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response | Q44663938 | ||
| 1H-MRSI of radiation effects in normal-appearing white matter: dose-dependence and impact on automated spectral classification | Q44666444 | ||
| Response criteria for phase II studies of supratentorial malignant glioma | Q44781447 | ||
| 3D 1H MRSI of brain tumors at 3.0 Tesla using an eight-channel phased-array head coil | Q44822572 | ||
| Cerebral blood flow: assessment with dynamic contrast-enhanced T2*-weighted MR imaging at 1.5 T. | Q44846132 | ||
| 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. | Q44849163 | ||
| Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma | Q45048159 | ||
| Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protoco | Q45090505 | ||
| Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma | Q45288600 | ||
| Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. | Q45997469 | ||
| Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. | Q46007003 | ||
| Dynamic susceptibility contrast perfusion imaging of radiation effects in normal-appearing brain tissue: changes in the first-pass and recirculation phases. | Q46024068 | ||
| Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations | Q46159406 | ||
| Accuracy of diffusion tensor magnetic resonance imaging tractography assessed using intraoperative subcortical stimulation mapping and magnetic source imaging | Q46205366 | ||
| An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma | Q46222206 | ||
| Partially parallel MR spectroscopic imaging of gliomas at 3T. | Q46302315 | ||
| Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival | Q46332916 | ||
| Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T-initial experience | Q46562029 | ||
| Unaliasing lipid contamination for MR spectroscopic imaging of gliomas at 3T using sensitivity encoding (SENSE). | Q46849145 | ||
| Taming glioblastoma: targeting angiogenesis | Q46942090 | ||
| Newly codified glial neoplasms of the 2007 WHO Classification of Tumours of the Central Nervous System: angiocentric glioma, pilomyxoid astrocytoma and pituicytoma | Q48122863 | ||
| Assessment of cerebral blood volume with dynamic susceptibility contrast enhanced gradient-echo imaging | Q48125908 | ||
| Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings | Q48145277 | ||
| Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging | Q48196331 | ||
| Localized proton spectroscopy of inoperable brain gliomas. Response to radiation therapy | Q48262253 | ||
| Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group | Q48271471 | ||
| Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas | Q48276582 | ||
| Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas | Q48334671 | ||
| Considerations in applying 3D PRESS H-1 brain MRSI with an eight-channel phased-array coil at 3 T. | Q48348165 | ||
| PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. | Q48359025 | ||
| Enhancing fraction in glioma and its relationship to the tumoral vascular microenvironment: A dynamic contrast-enhanced MR imaging study. | Q48375491 | ||
| Magnetic resonance perfusion and permeability imaging in brain tumors | Q48390514 | ||
| Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance | Q48401235 | ||
| Apparent diffusion coefficient histograms may predict low-grade glioma subtype. | Q48417771 | ||
| Evaluation of parenchymal changes at the operation site with early postoperative brain diffusion-weighted magnetic resonance imaging. | Q48421400 | ||
| Long-term normal-appearing brain tissue monitoring after irradiation using proton magnetic resonance spectroscopy in vivo: statistical analysis of a large group of patients | Q48430655 | ||
| Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. | Q48472714 | ||
| Angiogenic patterns and their quantitation in high grade astrocytic tumors. | Q48483837 | ||
| High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. | Q48491367 | ||
| Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas. | Q48503860 | ||
| In vivo single voxel 1H MRS of glial brain tumors: correlation with tissue histology and in vitro MRS. | Q48539533 | ||
| Transient metabolic changes observed with proton MR spectroscopy in normal human brain after radiation therapy. | Q48544829 | ||
| Characterization of low-grade gliomas using RGB color maps derived from ADC histograms. | Q48552322 | ||
| Apparent diffusion coefficient of human brain tumors at MR imaging | Q30987327 | ||
| Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma | Q31015437 | ||
| The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome | Q31043513 | ||
| Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology | Q31126719 | ||
| Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence | Q31148416 | ||
| Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas | Q31154294 | ||
| In vivo molecular imaging for planning radiation therapy of gliomas: an application of 1H MRSI. | Q33184714 | ||
| Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine | Q33210654 | ||
| Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide | Q33335220 | ||
| Phase II trial of temozolomide in patients with progressive low-grade glioma | Q33346531 | ||
| Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. | Q33356908 | ||
| Scan-rescan variability in perfusion assessment of tumors in MRI using both model and data-derived arterial input functions | Q33367620 | ||
| Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors | Q33368027 | ||
| End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria | Q33447142 | ||
| Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment | Q33475538 | ||
| Pseudoprogression and pseudoresponse in the treatment of gliomas | Q33505483 | ||
| Pattern recognition of MRSI data shows regions of glioma growth that agree with DTI markers of brain tumor infiltration | Q33507124 | ||
| Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging | Q33507482 | ||
| Intraoperative use of diffusion tensor imaging fiber tractography and subcortical mapping for resection of gliomas: technical considerations | Q33528083 | ||
| An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab | Q33568752 | ||
| Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma | Q33574572 | ||
| Analysis of metabolic indices in regions of abnormal perfusion in patients with high-grade glioma | Q33793833 | ||
| Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors | Q34132735 | ||
| Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme | Q34133089 | ||
| Glioblastoma cells release factors that disrupt blood-brain barrier features | Q34290788 | ||
| Implementation of 3 T lactate-edited 3D 1H MR spectroscopic imaging with flyback echo-planar readout for gliomas patients | Q34440284 | ||
| Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma | Q34480495 | ||
| Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy | Q34498046 | ||
| Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. | Q34498073 | ||
| The role of angiogenesis in tumor growth | Q34539790 | ||
| Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma | Q34562175 | ||
| Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme. | Q34977347 | ||
| Real-time metabolic imaging | Q34983950 | ||
| Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM | Q34992526 | ||
| Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption | Q34997337 | ||
| Convection-enhanced delivery of macromolecules in the brain | Q35091232 | ||
| Heat shock protein 90 as a molecular target for cancer therapeutics | Q35099516 | ||
| Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival | Q35698555 | ||
| Low-grade glioma: supratentorial astrocytoma, oligodendroglioma, and oligoastrocytoma in adults | Q35753037 | ||
| Response and progression in recurrent malignant glioma | Q35895167 | ||
| A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party | Q35993865 | ||
| Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy | Q36185748 | ||
| Diffusely infiltrative low-grade gliomas in adults | Q36416740 | ||
| Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings | Q36649062 | ||
| Quantitative metabolite patterns of human brain tumors: detection by 1H NMR spectroscopy in vivo and in vitro | Q36740560 | ||
| Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. | Q36796782 | ||
| New molecular targets in malignant gliomas | Q36997065 | ||
| Overcoming therapeutic resistance in malignant gliomas: current practices and future directions. | Q37072756 | ||
| Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. | Q37073257 | ||
| Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging | Q37126776 | ||
| Apparent diffusion coefficient and fractional anisotropy of newly diagnosed grade II gliomas | Q37168291 | ||
| PTEN signaling in brain: neuropathology and tumorigenesis. | Q37270423 | ||
| Novel anti-angiogenic therapies for malignant gliomas | Q37325086 | ||
| Heat-shock protein vaccines as active immunotherapy against human gliomas | Q37331708 | ||
| Multiparametric characterization of grade 2 glioma subtypes using magnetic resonance spectroscopic, perfusion, and diffusion imaging | Q37429908 | ||
| Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma multiforme. | Q37641988 | ||
| Perfusion imaging by nuclear magnetic resonance | Q38787994 | ||
| Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading | Q39301749 | ||
| DNP-Hyperpolarized C Magnetic Resonance Metabolic Imaging for Cancer Applications | Q39320582 | ||
| Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma | Q39476804 | ||
| An analysis of dose-effect relationship in the radiotherapy of malignant gliomas | Q40285820 | ||
| Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme | Q40531161 | ||
| The new WHO classification of brain tumours | Q40807273 | ||
| Angiogenesis in brain tumors; pathobiological and clinical aspects | Q41363025 | ||
| A preliminary study of the prognostic value of proton magnetic resonance spectroscopic imaging in gamma knife radiosurgery of recurrent malignant gliomas | Q41721677 | ||
| GRAPPA-based susceptibility-weighted imaging of normal volunteers and patients with brain tumor at 7 T. | Q41832566 | ||
| Localised proton spectroscopy and spectroscopic imaging in cerebral gliomas, with comparison to positron emission tomography | Q42480177 | ||
| (1)H spectroscopic imaging of human brain at 3 Tesla: comparison of fast three-dimensional magnetic resonance spectroscopic imaging techniques | Q42594149 | ||
| Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report | Q42665094 | ||
| Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence | Q42686851 | ||
| Correlations between in vivo (1)H MRS and ex vivo (1)H HRMAS metabolite measurements in adult human gliomas | Q43184820 | ||
| Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens | Q43566939 | ||
| Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery | Q43566942 | ||
| P433 | issue | 6 | |
| P921 | main subject | magnetic resonance imaging | Q161238 |
| brain tumor | Q233309 | ||
| P304 | page(s) | 734-749 | |
| P577 | publication date | 2011-04-27 | |
| P1433 | published in | NMR in Biomedicine | Q3061252 |
| P1476 | title | Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. | |
| P478 | volume | 24 |
| Q34280336 | 3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy |
| Q49830313 | A fuzzy feature fusion method for auto-segmentation of gliomas with multi-modality diffusion and perfusion magnetic resonance images in radiotherapy. |
| Q26826862 | Advanced magnetic resonance imaging methods for planning and monitoring radiation therapy in patients with high-grade glioma |
| Q30847284 | Advanced magnetic resonance imaging of the physical processes in human glioblastoma |
| Q31076319 | Advanced neuroimaging in the clinic: critical appraisal of the evidence base |
| Q30358150 | Advances in diagnostic and treatment modalities for intracranial tumors. |
| Q39817583 | Characterization of the serum metabolome following radiation treatment in patients with high-grade gliomas |
| Q35028897 | Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab |
| Q37014722 | Comparison of DSC-MRI post-processing techniques in predicting microvascular histopathology in patients newly diagnosed with GBM |
| Q30575323 | Convex non-negative matrix factorization for brain tumor delimitation from MRSI data |
| Q26853308 | Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients |
| Q34517492 | Delayed contrast extravasation MRI for depicting tumor and non-tumoral tissues in primary and metastatic brain tumors |
| Q35788925 | Delayed contrast extravasation MRI: a new paradigm in neuro-oncology |
| Q52091021 | Diagnostic accuracy of proton magnetic resonance spectroscopy and perfusion-weighted imaging in brain gliomas follow-up: a single institutional experience. |
| Q35888150 | Differentiating Radiation-Induced Necrosis from Recurrent Brain Tumor Using MR Perfusion and Spectroscopy: A Meta-Analysis |
| Q28067114 | Diffusion and perfusion weighted magnetic resonance imaging for tumor volume definition in radiotherapy of brain tumors |
| Q30582849 | Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis |
| Q38990221 | Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma |
| Q38867300 | IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. |
| Q40116790 | Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI. |
| Q38680891 | In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells |
| Q31136705 | Interrogating Metabolism in Brain Cancer. |
| Q38969526 | Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma |
| Q39312420 | MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives. |
| Q37168287 | Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas |
| Q48341221 | Measuring clinical benefit: use of patient-reported outcomes (PRO) in primary brain tumor clinical trials. |
| Q33844943 | Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment |
| Q37312731 | Multivoxel ¹H MR spectroscopy is superior to contrast-enhanced MRI for response assessment after anti-angiogenic treatment of orthotopic human glioma xenografts and provides handles for metabolic targeting |
| Q37537230 | Non-invasive in vivo assessment of IDH1 mutational status in glioma. |
| Q30613603 | Nuclear Overhauser enhancement (NOE) imaging in the human brain at 7T. |
| Q28541749 | Nuclear overhauser enhancement mediated chemical exchange saturation transfer imaging at 7 Tesla in glioblastoma patients |
| Q37609463 | Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma. |
| Q34289982 | Radiosurgery for high-grade glioma. |
| Q34367593 | Review of treatment assessment using DCE-MRI in breast cancer radiation therapy |
| Q37348479 | Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab |
| Q47412810 | Simultaneous QSM and metabolic imaging of the brain using SPICE. |
| Q103760067 | The Utilization of Treatment Response Assessment Maps in Discriminating Between Radiation Effect and Persistent Tumoral Lesion in Metastatic Brain Tumors Treated with Gamma Knife Radiosurgery |
| Q28608269 | The comprehensive neuro-oncology data repository (CONDR): a research infrastructure to develop and validate imaging biomarkers |
| Q36326284 | Watching tumours gasp and die with MRI: the promise of hyperpolarised 13C MR spectroscopic imaging |
Search more.